Política: Oil prices fell while negotiations showed possible progress.
President Donald Trump met Qatar's prime minister on November 9. After the meeting, Trump said that renewed U.S. attacks appeared unlikely if negotiations continued to make progress. However, officials warned that the sides had not reached an immediate final agreement.
Iran proposed several early steps that could help build confidence. It offered to stop blocking the Strait of Hormuz. Tehran also proposed an end to the U.S. blockade and asked for some sanctions to be lifted. Nuclear negotiations would take place after these first measures.
The Strait of Hormuz is an important route for petroleum shipments, but it remains partly disrupted. Any change there could affect the movement of oil. Brent crude fell by 5.8% and reached $92.57 per barrel. Earlier in November, the price had risen above $112 per barrel.
The change in oil prices came as financial markets improved. U.S. stocks recovered much of the losses they had suffered during the previous week. Still, the situation remained uncertain because the first confidence-building measures had not produced a final deal. Further progress depended on negotiations and action from the sides involved.
Escrito a partir destas notícias: Trump after meeting with Qatari PM says he believes war with Iran is militarily 'effectively over' · Trump to meet Iran war mediator Qatar, no imminent deal seen to end the war · US stocks rally and recover most of last week's losses as oil prices swing lower · Oil falls as Trump downplays prospect of escalation with Iran
Economia: US stocks rose strongly as geopolitical tensions eased
US stocks rose strongly on November 9 after falling the week before. The S&P 500, a broad measure of large US stocks, gained 2.3%. The Nasdaq, an index with many technology companies, rose 2.7%. The Dow, an index of 30 major companies, jumped 1,104 points, or 2.2%. All eleven S&P 500 sectors, or industry groups, increased. Industrials led with a 3.8% gain. However, the recovery followed a difficult week. The S&P 500 had fallen 2.7%, the Nasdaq had dropped 3.4%, and the Dow had declined 0.9%. Technology had been the weakest major sector, falling 6.9%. The Nasdaq also remained nearly 12% below its October 6 record.
Economic information gave investors several points to consider. October payrolls, which measure the number of jobs added, increased by 165,000, while unemployment fell to 4.1%. Markets priced in a 78% probability that the Fed would raise interest rates on December 9. A rate hike means an increase in the cost of borrowing money. The 10-year Treasury yield, the return paid by a long-term US government bond, rose to 4.87% Monday. Investors were also waiting for October CPI and core CPI on Tuesday, November 10. These reports measure changes in consumer prices, with core CPI leaving out food and energy. The relationship between oil and yields had recently turned negative, near minus 10%.
Geopolitical risk became less serious on Monday. Trump called the Iran war militarily effectively over. Hopes for de-escalation, meaning a reduction in conflict, helped push oil prices lower. WTI crude, a major US oil price, had already fallen 13% during the previous week as Iran-war tensions eased. However, the U.S. blockade continued to restrict Iranian oil exports. This showed that an important part of the conflict remained in place even as military tensions appeared to decrease.
Measures of fear gave a mixed picture of risk appetite, or investors' willingness to hold less safe assets. The VIX, an index that measures expected stock-market changes and is often called a fear measure, closed near 19.92 after falling 22.31%. This large decline suggested less immediate market fear. However, CNN Fear and Greed stood at 29, which was still in fear territory. Bitcoin exchange-traded funds, or ETFs that hold assets linked to Bitcoin, recorded $412 million of outflows Monday. Outflows are money leaving an investment. These funds lost nearly $1.9 billion across two sessions.
Most Magnificent Seven stocks rose. This group represented nearly 40% of the S&P 500's weighting, or its influence on the index. Apple gained 2.43%, Microsoft rose 2.75%, Alphabet added 1.18%, Amazon gained 2.9%, Meta climbed 5.12%, and Tesla jumped 5.54% after earlier election-related losses. No specific catalyst, or event causing a price move, was reported for Apple or Meta. Oracle capacity reductions remained news for Microsoft, while Anthropic pursued alternative AI infrastructure related to Amazon. Google's AI-chip push pressured Nvidia, which fell 4.27% despite the wider technology rebound.
Overall, easing Iran-war tensions appear to have moved the market most because they were linked directly to lower oil prices, while every S&P 500 sector rose and fear fell sharply. Strong gains among six Magnificent Seven companies also supported the indexes because of the group's large weighting. Still, the high probability of a Fed rate hike, the rising Treasury yield, continued fear readings, Bitcoin ETF outflows, and the upcoming inflation reports gave investors reasons to remain careful.
Escrito a partir destas notícias: How major US stock indexes fared Monday 11/9/2026 · Microsoft Word - 11082026 Weekly Market Commentary · Oil prices and bond yields no longer moving together · Closing Tape — 2026-11-09 · US Markets Briefs: Pre-market brief — Saturday, November 7, 2026 · US STOCKS-Nasdaq rebounds but posts fourth straight weekly decline · Market Snapshot November 9th 2026
Esportes: Carlos Alcaraz wins his first Paris Masters title
Carlos Alcaraz defeated Ben Shelton in the Paris Masters final on Sunday. The Spaniard won the match 7-6, 7-5 to claim his first title at the tournament. The final lasted one hour and 57 minutes, and both sets were close.
The result gave Alcaraz his ninth ATP Masters 1000 trophy. It was also his fifth title of the 2026 season. His success in Paris continued a strong period for him after he won the tournament in Vienna. These were his second and third consecutive tournament victories.
The match came after a different result between the two players in September. Shelton had beaten Alcaraz in the quarter-final of the US Open. However, Alcaraz won their latest meeting in two sets and added another important trophy to his season.
The Paris victory was also important because Alcaraz had recently returned to competition. He had been recovering from a wrist injury before his return. His next event will be the ATP Finals in Turin, where he will continue his 2026 season after winning two tournaments in a row.
Escrito a partir destas notícias: Alcaraz beats Shelton in Paris Masters final for his fifth title this year · Carlos Alcaraz defeats Ben Shelton to win first Paris title · Carlos Alcaraz beats error-prone Ben Shelton to win Paris Masters · Alcaraz, Paris' young prince
Ciência: The FDA adds vision warnings to four medicines.
The US Food and Drug Administration (FDA) announced a labeling change on Monday, November 9, 2026. New warnings will cover Ozempic, Wegovy, Mounjaro and Zepbound. The warnings will be added to prescribing information for medical professionals and to materials for patients.
The change concerns a rare condition that affects the optic nerve. This nerve carries information from the eye to the brain. The condition is called non-arteritic anterior ischemic optic neuropathy. It can cause vision loss, and some cases may lead to permanent problems with sight.
The FDA reviewed information from more than 125 clinical trials. The evidence mainly concerns medicines containing semaglutide or tirzepatide. After one year, about six patients out of every 100,000 developed the optic-nerve condition. This means that the condition was uncommon in the trial data.
The new labeling will help patients and medical professionals learn about the possible vision problem. Patients who notice sudden changes in their vision should report them promptly. They should also report vision that is becoming worse. The updated patient materials will include this advice, while the prescribing information will provide the warning to medical professionals.
Escrito a partir destas notícias: FDA adds rare vision-loss warning to popular GLP-1 drugs · US FDA orders new eye risk warnings for Ozempic, Zepbound